Eastman Kodak Company: Q1 1995 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1995. Eastman Kodak Company reported strong financial performance driven by volume gains in imaging products and favorable foreign currency effects. The company continues to divest non-imaging health businesses, which are reported as discontinued operations.
Key Financial Metrics
| Metric (in millions) | Q1 1995 | Q1 1994 |
|---|---|---|
| Total Revenues | $3,209 | $2,779 |
| Sales | $3,137 | $2,755 |
| Net Earnings | $262 | $82 |
| Earnings Per Share (Diluted) | $0.76 | $0.24 |
| Gross Profit Margin | 48.6% | 46.7% |
| Operating Cash Flow | $204 | ($28) |
| Cash and Equivalents (End of Period) | $573 | $1,163 |
| Total Debt (Short + Long Term) | $1,025 | N/A |
Note: Total debt calculated as Short-term borrowings ($373M) + Long-term borrowings ($652M).
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 14% year-over-year to $3,137 million. Excluding the acquisition of Qualex, organic sales from continuing operations grew 9%.
- Profitability Surge: Net earnings tripled to $262 million from $82 million. Earnings from continuing operations rose 81% to $262 million.
- Cash Position: Cash and cash equivalents dropped significantly from $2,020 million at year-end 1994 to $573 million. This decrease is primarily attributed to approximately $1.3 billion in tax payments related to the divestiture of non-imaging health businesses.
- Segment Performance:
- Consumer Imaging: Sales up 27% (U.S. +47%, International +17%). Operating earnings up 48%.
- Commercial Imaging: Sales up 7% (U.S. +2%, International +12%). Operating earnings up 18%.
- Discontinued Operations: The prior year included a $51 million loss from discontinued operations and a $12 million extraordinary charge related to debt extinguishment, neither of which impacted 1995 results.
Outlook, Risks, and Management Commentary
- Outlook: Management projects operating cash flows will be adequate to support normal operations, planned capital expenditures ($238M in Q1), and dividend payments ($136M declared in Q1).
- Divestitures: The company announced an agreement to sell its pharmaceutical R&D facility to SmithKline Beecham for $120 million. Proceeds are expected to align with estimates.
- Risks and Contingencies:
- Environmental: Kodak is a participant in the EPA's TSCA Compliance Audit Program, anticipating a $1 million liability. It is also a potentially responsible party (PRP) at approximately 25 Superfund sites; however, management expects future costs to be immaterial.
- Legal: The company is involved in various lawsuits and claims (product liability, commercial, environmental) but does not expect any pending matters to be material.
- Unusual Items: The significant drop in cash balances is a one-time event driven by tax liabilities from prior year divestitures, not operational cash burn.
Investor Verification Checklist
- Verify the sustainability of the 14% sales growth excluding the one-time impact of Qualex integration.
- Confirm the timing and amount of the $1.3 billion tax payment related to health business divestitures to ensure cash flow projections are accurate.
- Monitor the closing of the $120 million sale of the pharmaceutical R&D facility to SmithKline Beecham.
- Review the status of environmental liabilities at the 25 Superfund sites to ensure costs remain immaterial as stated.
- Assess the impact of foreign currency fluctuations, which contributed $127 million to sales, on future quarters if exchange rates reverse.